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Abstract: In this work, the behavior of the active pharmaceutical substances 
methylprednisolone (in a form of methylprednisolone sodium succinate) in fi-
nished pharmaceutical dosage form, i.e., freeze-dried powder for injections, 
was examined. The goal was to evaluate the chemical stabilities of methylpre-
dnisolone sodium succinate packaged in a dual chamber vial, as a specific con-
tainer closure system. The effect of different parameters: temperature, moisture 
and light were monitored. The method proposed by United States Pharma-
copeia was used to determine concentrations of methylprednisolone, as the sum 
of the concentration of methylprednisolone esters (17-hydrogen succinate and 
21-hydrogen succinate) and free methylprednisolone. The HPLC method was 
used for stability evaluation of the active substance and determination of re-
lated substances. Four main degradation products were registered. Temperature 
has a major impact on the degradation process with the appearance of 3 degra-
dation products (impurities B, C and D), while the presence of light caused an 
increasing content of impurity A. Identification of impurity B, C and D has 
been realized using mass and NMR spectroscopy. All three substances are 
substances related to methylprednisolone. 
Keywords: methylprednisolone sodium succinate; freeze-dried powder; con-
tainer closure system; stability; impurities. 
INTRODUCTION 
Methylprednisolone (MP) is a synthetically produced glucocorticoid with a 
structure similar to that of a natural hormone produced by the adrenal glands. 
Like most adrenocortical steroids, MP is typically used in replacement therapy for 
adrenal insufficiency and as an anti-inflammatory and immunosuppressant agent. 
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MP (Fig. 1A) belongs to the group of corticosteroids which are hydroxyl 
compounds (alcohols). Both, free alcohol and ester (Fig. 1B) occur as odorless, 
white or almost white, crystalline powder. They are practically insoluble in water 
and sparingly soluble in alcohol. The sodium salt of the phosphate or succinate 
ester is generally used to provide water-soluble forms for injections or solutions. 
 
Fig. 1. Structure of MP (A), MP 21-HS (B), MP 17-HS (C), impurity B (D), 
impurity B1 (E), and impurities C and D (F). 
In pharmacopeias there are several referenced chemical substances: MP, me-
thylprednisolone acetate, methylprednisolone hydrogen succinate (MP 21-HS)1–4 
and methylprednisolone sodium succinate (MPNaS).3 
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Among all the cited substances, only MPNaS may be given intravenously. 
MPNaS is so extremely soluble in water3 that it may be administered in a small 
volume of diluents and is especially well suited for intravenous use in situations 
in which high blood levels of MP are required rapidly and oral therapy is not pos-
sible.5 The chemical name for MPNaS is (6α,11β)-11,17,21-trihydroxy-6-methyl- 
-pregna-1,4-diene-3,20-dione-monosodium salt and the molecular weight is 
496.53 g mol–1. 
MP is a very unstable substance, especially in the presence of moisture.6–10 
This is the main reason for using the lyophilization process for production of in-
jections. A problem associated with this type of injection is the storage of the me-
dications (powder and solution for reconstitution) that should be administered as 
separate component parts and mixed prior to injection. Therefore, dual chamber 
vials have been developed to facilitate the storage and mixing of such two-com-
ponent medications. This container closure system consists of a glass vial with two 
chambers separated by an intermediate rubber closure and an upper closure on 
the top. The specific feature of this type of the products is that both the lyophi-
lized active ingredient (in the lower chamber) and the solution for reconstitution 
(in the upper chamber) are in the same vial. 
MP and its derivatives are well known and defined, not only in Pharmaco-
peias, but in official documentations of the manufacturers and in the literature as 
well.11–13 Although a number of studies of the physical and chemical stabilities 
of MPNaS have been reported,14–19 no published information is available on its 
stability in a dual chamber vial. 
The objective of this work was to evaluate the chemical stability of lyophi-
lized injectable preparation of MPNaS. The last step to reach our goal was to 
check the influence of all critical points on the degradation profile of MP. Special 
consideration was given to changes in the concentration of the active substance 
(total MP), the concentration of free MP, determination of related substances as 
possible degradation products and also their identification. 
EXPERIMENTAL 
Materials 
A lyophilized injectable preparation of MPNaS was purchased by Hemofarm, Vršac, 
Serbia. The solution for reconstitution was water for injection/ 0.9 % benzyl alcohol. Two 
milliliters of reconstituted solution contained MPNaS equivalent to 125 mg MP, phosphate 
buffer and benzyl alcohol. This product was tested in the early development phase in accor-
dance with relevant guidelines.20–26 
All solvents, n-butyl chloride (Merck, Germany), tetrahydrofuran (Sigma-Aldrich, Ger-
many) methanol (Merck, Germany), glacial acetic acid (Sigma-Aldrich, Germany) and chlo-
roform (Merck, Germany) were of a grade suitable for high-performance liquid chroma-
tography (HPLC) analysis. MP 21-HS (Aventis Pharma, France), MP and fluorometholone 
reference standards (RS) were obtained commercially. The reference standard was used 
without further purification. 
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All samples were conditioned according to the requirements of the International Con-
ference on Harmonization Standards for Stability (Q1A)21 and Photostability (Q1B UV).26 
The following chambers were used: Weiss 2000, Weiss Gallenkamp, Weiss 600, Weiss Gal-
lenkamp, Sanyo PSC 062, Sanyo Gallenkamp (Great Britain) and Weiss Umwelttechnik 140, 
Weiss Umwelttechnik, Germany. 
Procedure for stability testing 
A stability study was designed to increase the rate of chemical degradation of the 
finished pharmaceutical product (FPP) by using exaggerated storage conditions as part of the 
formal stability studies. The acceleration conditions used in this study are presented in Table I. 
During the study, the vials were kept in an upright or in a horizontal position. The horizontal 
position was chosen for compatibility assessment, in other words to ensure maximal contact of 
the diluent of the subject drug product with the elastomeric closures. 
TABLE I. Storage conditions and testing frequencies 
Storage conditions Storage orientation Testing time points, months 
Accelerated 40±2 °C/75±5 % RHa Upright 0, 1, 2, 3 and 6 
Horizontal 0, 3 and 6 
Intermediate 30±2 °C/65±5 % RH Upright 0, 3, 6, 9 and 12 
Horizontal 0, 6 and 12 
Long-term 25±2 °C/60±5 % RH Horizontal 0, 12, and 24 
aRelative humidity 
The in-use stability24,25 was evaluated by examining the quality parameters of the subject 
drug product susceptible to change at the end of the proposed in-use shelf life (i.e., 48 h after 
reconstitution, kept at room temperature). The samples were tested immediately after pro-
duction (initial test point), at the end of the accelerated and intermediate conditions and at 12 
and 24 month-testing points during long-term testing. 
Photostability testing was performed using a light source – Option 2.26 This means that a 
cool white fluorescent lamp and a near UV fluorescent lamp were used. The vials were ex-
posed to light providing a defined energy (1.2×106 lx h) and then reconstituted. At the same 
time, protected samples (vials wrapped in aluminum foil or kept in a cardboard box) were 
used as the dark controls. At the end of this phase, the concentration of MP and related 
substances was determined. 
Methods 
HPLC Method for MP determination. Analytical procedures for the determination of 
both the total MP and free MP were in accordance with USP 32. The concentration of total 
MP is expressed as the sum of the concentration of free MP, MP 21-HS and MP 17-HS. The 
concentration of free MP is separately expressed as it is an important degradation product. 
The analyses were performed on an HPLC system, Agilent Technology 1100 Series, equipped 
with a 254 nm detector and a column packed with porous silica particles (L3). The flow rate 
was 1.0 mL min-1. The mobile phase was prepared by mixing butyl chloride, water-saturated 
butyl chloride, tetrahydrofuran, methanol and glacial acetic acid (95:95:14:7:6; volume ratio).  
An internal standard solution of concentration 3 mg mL-1 was obtained by dissolving the 
required amount of fluorometholone (RS) in tetrahydrofuran. 
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An MP solution was prepared by transferring an accurately weighed amount of MP RS 
(about 7.5 mg) to a 25-mL volumetric flask and dissolving to the mark with solvent. The 
solvent was 3 % glacial acetic acid in chloroform. 
A standard solution was prepared by transferring an accurately weighed amount of MP 
21-HS RS (about 32.5 mL) to a 50-mL volumetric flask. 5 mL of internal standard solution 
and 5 mL of MP solution were added. Solvent was added up to 50 mL. 
A test solution was prepared as follows. The tested product was reconstituted according 
to the manufacturer’s directions. Aliquots of 10 vials were collected and 0.8 mL of this so-
lution was transferred to a 100-mL volumetric flask. The internal standard solution (10 mL) 
was added and the mixture was diluted with solvent to the mark. After 5 minute shaking, the 
layers were separated and the upper one was discarded.  
The injection volume was 10 µL of each sample. 
HPLC Method for determination of related substances. The related substances were 
determined by an isocratic HPLC method using an Agilent 1100 Series instrument with a 
variable wavelength UV–Vis detector. Separation was realized on a C18 column (250 
mm×4.6 mm, 5 µm) column at a flow rate of 1.2 mL min-1. The mobile phase was prepared by 
combining acetic acid, acetonitrile, and purified water (2:30:75, volume ratio).  
A test solution was prepared as follows. Reconstituted solutions prepared from the con-
tents of 10 vials of MPNaS for injection were mixed and 0.4 mL was transferred to a 20-mL 
volumetric flask and diluted with mobile phase up to 20 mL. The concentration of the ob-
tained solution was 0.1 % w/v. 
A standard solution was prepared by transferring 1 mL of test solution to a 100-mL vo-
lumetric flask and diluting with mobile phase. Then 1 mL of this solution was diluted with 
mobile phase to 10 mL. The concentration of the standard solution was 0.0001 % w/v. 
The injection volume was 20 µl of each sample. 
Methods for identification of related substances. Samples were treated with 5 mol L-1 
HCl for 30 min at 80 °C in order to force degradation and obtain higher concentrations of the 
degradation products.  
The samples of the degradation products were obtained from the reaction mixture by 
semi-preparative HPLC. The same apparatus was used (Agilent 1100 Series), with a variable 
wavelength UV–Vis detector, but a semi-preparative Zorbax Eclipse XDB-C18 (250 mm×9.4 
mm; 5 μm) column was used; the flow rate was 4.0 mL min-1 and the injection volume was 
1000 µL. The mobile phase was prepared by combining formic acid and acetonitrile (7:3, v/v).  
The high resolution electrospray ionization in a time of flight (HR-ESI-TOF) mass spec-
tra of MP and three degradation products were measured on an Agilent 6210 LC/MS ins-
trument. The mass spectrometer was operated under the following conditions: source – ESI in 
the positive/negative mode, dry gas: 12.0 L min-1, dry temperature: 350 °C, nebulizer: 45 psig, 
scan: 100–1500 m/z, fragmentor: 140 V, capillary voltage: 4000 V. 
The 1H-NMR spectra of impurities C and D were measured on a Varian Gemini 2000 
instrument at 200 MHz in CDCl3. The NMR spectra of MP and impurity B (1H-, 13C-, DEPT- 
-135, COSY, NOESY, HSQC and HMBC) were measured on a Bruker Avance III instrument 
at 500 MHz in CDCl3 (a few drops of CD3OD were added for MP). 
RESULTS AND DISCUSSION 
Assay MP and related substances determination 
A chromatogram of the test solution obtained during assay determination is 
presented in Fig. 2. The order of the elution of peaks is the internal standard 
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peak, MP 21-HS peak and successive smaller peaks of free MP and methylpred-
nisolone 17-hydrogen succinate (MP 17-HS). The concentration of total MP is 
expressed as the sum of the concentration of free MP, MP 21-HS and MP 17-HS 
(Fig. 1C). The concentration of total MP in the initial sample (in the form of so-
dium succinate) was defined as 100 %, and subsequent sample concentrations 
were expressed as percentage of the initial concentration. 
 
Fig. 2. Chromatogram of the MP test solution; fluorometholone was used 
as the internal standard. 
The HPLC method for the determination of related substances confirmed the 
existence of four specified and not identified impurities marked as impurity A, B, 
C and D. A typical chromatogram related to the impurities is presented in Fig. 3. 
The second part of this study was focused on the identification of these im-
purities. 
The influences of different temperature in terms of the concentration of total 
MP, free MP and related substances are given in Tables II and III. All results are 
related to horizontal positioned vials. As can be seen, increasing the temperature 
was followed by an increase of free MP (because of hydrolysis) but it was still 
significantly below the maximum allowed level of 6.6 %. The obtained results in-
dicated that there were no changes in the content of total MP, which could in-
fluence the shelf life. 
An increase in the concentrations of the related substances was also regis-
tered. After 6 months conditioning at 40 °C/75 % relative humidity (RH), the 
concentrations of impurity B and impurity D were above 0.15 %, which is the 
identification level in accordance with relevant guidelines.27 The increase in the 
concentration of impurity A was not significant. 
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Fig. 3. Chromatogram of related substances – impurities A, B, C and D are considered as 
related substances: the sample was treated at 40 °C/75 % RH for 3 months and prepared as 
described in the method for determination of related substances (test solution). 
TABLE II. Results for the concentration of total MP/free MP (percent of the labeled amount 
of MP) under different storage conditions 
Storage conditions Initial result Intermediate result Final result 
40 °C/75 % RHa 101.9/1.51 101.3/2.70 100.4/3.12 
30 °C/65 % RH 101.9/1.51 100.9/2.21 102.1/2.89 
25 °C/60 % RH 101.9/1.51 101.8/2.04 101.3/2.68 
aRelative humidity 
TABLE III. Results of the determination of the related substances (presented as percent of 
labeled amount of MP) 
Storage conditions Related substance Initial result Intermediate result Final result 
40 °C/75 % RHa A 
B 
C 
D 
<LODb 
0.03 
0.03 
0.04 
0.03  
0.22 
0.11 
0.15 
0.04 
0.25 
0.14 
0.21 
30 °C/65 % RH A 
B 
C 
D 
<LOD 
0.03 
0.03 
0.04 
<LOD 
0.10 
0.06 
0.10 
0.05 
0.14 
0.08 
0.12 
25 °C/60 % RH A 
B 
C 
D 
<LOD 
0.03 
0.03 
0.04 
0.03 
0.10 
0.06 
0.09 
0.06 
0.13 
0.08 
0.12 
aRelative humidity; blimit of detection 
For the testing of the in-use stability, all samples are conditioned according 
to ICH requirements and reconstituted. The samples were analyzed initially (im-
mediately after production in use) and at the end after conditioning under defined 
conditions. The measurements on day 0 served as the references. The obtained 
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results are presented in Table IV. There were no statistically significant changes 
in the tested parameters – if the solution was kept at room temperature, there was 
no influence of water during 48 h; hence, only the results immediately after pro-
duction (initial test point) and after 6 months conditioning at 40 °C/75 % RH are 
presented. 
TABLE IV. Results of the in-use testing 
Tested parameters 
Immediately after production 
(initial test point) 
Final test (after 6 months 
conditioning at 40 °C/75 % RH) 
0 h 48 h 0 h 48 h 
Total MP concentration, % 101.9 99.6 100.4 100.2 
Free MP concentration, % 1.51 3.62 3.12 4.98 
Related substances, % 
Impurity A 
Impurity B 
Impurity C 
Impurity D 
<LODa 
0.03 
0.03 
0.04 
0.01 
0.04 
0.04 
0.06 
0.04 
0.25 
0.14 
0.21 
0.03 
0.25 
0.14 
0.20 
aLimit of detection 
The results of the photostability testing are summarized in Table V. It was 
concluded that there was a change in the tested parameters. It is obvious that im-
purity A increased while the concentration of total MP decreased. When vials are 
kept in the dark (wrapped in aluminum foil or kept in a cardboard box), the in-
crease in the concentration of impurity A was not significant; hence, impurity A 
was not the subject of further identification. 
TABLE V. Results of the photostability testing 
Tested parameters Initial Directly exposed vials Protected vials 
Total MP concentration, % 101.9 96.3 100.3 
Free MP concentration, % 1.51 1.58 1.64 
Related substances, % 
Impurity A 
Impurity B 
Impurity C 
Impurity D 
<LODa 
0.03 
0.03 
0.04 
0.32 
0.03 
0.04 
0.07 
0.01 
0.05 
0.04 
0.06 
aLimit of detection 
Identification of the structures of the degradation products 
From the retention times of the impurities, it was concluded that impurity B 
was less polar then MP, and impurities C and D were significantly less polar. 
Previous investigations of impurity B by MS showed that this compound has 
a mass of 374 amu, i.e., the same as MP. The most abundant ion in HR-ESI-TOF 
mass spectra of MP is the ion at m/z 375.2464 (M+H+), followed by 771.4071 
(2M+Na+) and 357.2057 (M+H+–H2O). The same ions appear in the mass spec-
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trum of impurity B, which means that impurity B and MP have the same mole-
cular formula, i.e., they are isomers. The presence of other ions (343, 345, 387...) 
in the mass spectrum of B showed that impurity B was impure and started to 
decompose. Hence, additional analyses (i.e., 1H-, 13C-, DEPT-135, COSY, NOESY, 
HSQC and HMBC NMR spectroscopy) were required in order to elucidate the 
structure of impurity B. 
Compound B had same mass and similar polarity as MP, so its structure 
could be 17-deoxy-21,21-dihydroxy-6α-methylprednisolone (Fig. 1D). The same 
compound was defined as impurity B of MP in EP.1 In the European Pharma-
copoeia this compound was defined as an impurity of MP and designated as B. 
It was assumed that MP initially gave impurity B, which was later trans-
formed (by standing and/or solvent exchange) into impurity B1. Since the struc-
ture of impurity B1 was not compatible with the chromatographic behavior and 
mass spectra of impurity B, the structure of impurity B1 was determined unequi-
vocally by NMR spectroscopy. 
The 1H-NMR spectrum of B1 (Fig. 4) is similar to that of MP, showing that 
they have the same basic structure. Based on all the spectra, it can be concluded 
that instead of a –CH2OH group at 21 and an –OH group at 17 in MP, impurity 
Bl has a –CHO group at 21 and an H-atom at 17. Thus Bl has the structure of 17- 
-deoxy-21-dehydro-6α-methylprednisolone (Figure 1E). The same impurity is 
known in the literature as an impurity of 6α-methylprednisolone acetate.28  
 
Fig. 4. 1H-NMR Spectrum of impurity B. 
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The 1H-NMR spectra of impurities C and D were very similar; they differed 
slightly in their chemical shifts. Compared to the proton spectrum of MP, the sig-
nals from the diastereotopic protons at C-21 were missing and a new signal ap-
peared at 9.71 ppm in the spectrum of C and at 9.56 in the spectrum of D. This 
means that C and D are isomeric aldehydes (Fig. 1 F). The spectral data of C and 
D are in very good agreement with data for isomeric enol aldehydes obtained 
from prednisolone. Thus C and D can be identified as the E and Z (respectively) 
20-hydroxy-17(20) E-ene-21-al derivatives of 6α-methylprednisolone, which was 
defined as impurity D of MP in EP.1 
According to the obtained results, the proposed degradation profile of MP is 
shown in Fig. 5. 
 
Fig. 5. Proposed degradation profile of MP. 
CONCLUSIONS 
Even if MP is a well known substance, it is still a subject of many studies 
especially regarding stability. In this work degradation profile in the freeze-dried 
product is presented. It is obviously clear that the temperature has influence on 
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degradation process, as well as light. Three of four detected degradation products 
are increasing under the temperature treatment. During this study it is confirmed 
that they are derivatives of the MP and at the same time defined as MP impurities 
in the Monograph in EP. The concentration of impurity A increases in the pre-
sence of light.  
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И З В О Д  
МЕТИЛПРЕДНИЗОЛОН И ЊЕГОВЕ СРОДНЕ СУПСТАНЦЕ У 
ЛИОФИЛИЗАТУ ЗА РАСТВОР ЗА ИНЈЕКЦИЈЕ 
ЉИЉАНА СОЛОМУН1, СВЕТЛАНА ИБРИЋ2, ВЛАТКА ВАЈС3, ИВАН ВУЧКОВИЋ3 и ЗОРИЦА ВУЈИЋ2 
1Hemofarm, A.D. Vr{ac 2Farmaceutski fakultet, Beograd i 3Hemijski fakultet, Beograd 
У овом раду испитиване су особине фармаколошки активне супстанце метилпредни-
золона (у облику метилпреднизолон-натријум-сукцината) у готовом производу – лиофили-
зату за раствор за инјекције. Циљ рада је испитивање хемијске стабилности метилпредни-
золон-натријум-сукцината у двокоморној бочици, као специфичном систему контактног па-
ковања. Испитан је ефекат различитих параметара: температуре, влаге и светлости. За одре-
ђивање концентрације метилпреднизолона, као збирне концентрације метилпреднизолон ес-
тара (17-хидроген-сукцината и 21-хидроген-сукцината) и слободног метилпреднизолона, ко-
ришћена је метода описана у Америчкој фармакопеји. За испитивање сродних супстанци 
примењена је HPLC метода. Уочена су 4 деградациона производа. Доказано је да повећање 
температуре има највећи значај на процес деградације и утиче на повећање садржаја нечис-
тоћа B, C и D, док присуство светлости доводи до повећања садржаја нечистоће А. Нечис-
тоће B, C и D су идентификоване применом масене и NMR спектроскопије. Све три нечис-
тоће су идентификоване као сродне супстанце метилпреднизолона. 
(Примљено 15. јануара, ревидирано 24. маја 2010) 
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